Volume 44, Issue 5 pp. 959-965
ORIGINAL ARTICLE

Potential of point of care tests for newborn screening for sickle cell disease: Evaluation of HemotypeSC™ and sickle SCAN® in Tanzania

Heavenlight Christopher

Corresponding Author

Heavenlight Christopher

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Correspondence

Heavenlight Christopher, Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam Tanzania.

Email: [email protected]

Search for more papers by this author
Emmanuel Josephat

Emmanuel Josephat

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Search for more papers by this author
Frida Kaywanga

Frida Kaywanga

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Search for more papers by this author
Sephord Saul

Sephord Saul

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Search for more papers by this author
Irene Mshana

Irene Mshana

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Search for more papers by this author
Peter Kunambi

Peter Kunambi

Department of Clinical Pharmacology, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Search for more papers by this author
Ahlam Nasser

Ahlam Nasser

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Search for more papers by this author
Clara Chamba

Clara Chamba

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Search for more papers by this author
Julie Makani

Julie Makani

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Search for more papers by this author
Siana Nkya

Siana Nkya

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Department of Biochemistry, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania

Tanzania Human Genetics Organization, Dar es salaam, Tanzania

Search for more papers by this author
First published: 01 July 2022
Citations: 2

Funding information: Organization for Women in Science for Developing world fund, Grant/Award Number: 4500384860; UK Aid/Department for International Development (DFID) through the Human Development Innovation Fund (HDIF), Grant/Award Number: HW2.0003

Abstract

Background

Sickle cell disease (SCD) is an important cause of <5 mortality. In Tanzania, it is estimated up to 11 000 children are born with SCD annually, making this the fifth country with the highest SCD annual births worldwide. The biggest challenge of expanding the service of newborn screening for SCD as the national health intervention in Tanzania is due to the high cost of the currently used assays and lack of rapid screening methods. Therefore, in this study, we assessed the diagnostic accuracy of point-of-care tests for SCD diagnosis in newborns.

Aim

To evaluate the sensitivity and specificity of HemotypeSC™ and sickle SCAN® in diagnosing SCD in newborns.

Methods

Diagnostic accuracy of HemotypeSC™ and sickle SCAN® were evaluated in comparison to isoelectric focusing as a confirmatory method.

Results

A total of 706 newborns were enrolled in the study. The sensitivity and specificity of HemotypeSC in detecting Hb SS, Hb AS and Hb AA phonotypes was 100%. The sensitivity and specificity of sickle SCAN® in detecting Hb SS, Hb AS and Hb AA phenotypes were 100%, 97% and 100% respectively.

Conclusion

Both POC tests displayed high accuracy in detecting SCD, we believe the introduction of either of these tests in health facilities will help in the early detection and management of SCD. In addition, the margin of cost per test is relatively affordable (1.4$ per test for HemotypeSC™ and 4.75$ for sickle SCAN®).

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

DATA AVAILABILITY STATEMENT

The data supporting the findings of this study are available within the article. Raw data that support the findings of this study are available from the corresponding author upon a reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.